- Home
- MCRB vs ALGS Comparison
MCRB vs ALGS Comparison
Compare MCRB & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- ALGS
- Stock Information
- Founded
- MCRB 2010
- ALGS 2018
- Country
- MCRB United States
- ALGS United States
- Employees
- MCRB N/A
- ALGS N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- MCRB Health Care
- ALGS Health Care
- Exchange
- MCRB Nasdaq
- ALGS Nasdaq
- Market Cap
- MCRB 141.9M
- ALGS 118.8M
- IPO Year
- MCRB 2015
- ALGS 2020
- Fundamental
- Price
- MCRB $0.80
- ALGS $18.63
- Analyst Decision
- MCRB Buy
- ALGS Strong Buy
- Analyst Count
- MCRB 4
- ALGS 1
- Target Price
- MCRB $5.63
- ALGS $75.00
- AVG Volume (30 Days)
- MCRB 844.5K
- ALGS 263.3K
- Earning Date
- MCRB 03-04-2025
- ALGS 03-11-2025
- Dividend Yield
- MCRB N/A
- ALGS N/A
- EPS Growth
- MCRB N/A
- ALGS N/A
- EPS
- MCRB N/A
- ALGS N/A
- Revenue
- MCRB $126,325,000.00
- ALGS $5,997,000.00
- Revenue This Year
- MCRB N/A
- ALGS N/A
- Revenue Next Year
- MCRB N/A
- ALGS N/A
- P/E Ratio
- MCRB N/A
- ALGS N/A
- Revenue Growth
- MCRB 12856.41
- ALGS N/A
- 52 Week Low
- MCRB $0.54
- ALGS $6.76
- 52 Week High
- MCRB $1.53
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- MCRB 46.38
- ALGS 33.33
- Support Level
- MCRB $0.81
- ALGS $20.12
- Resistance Level
- MCRB $0.84
- ALGS $24.33
- Average True Range (ATR)
- MCRB 0.04
- ALGS 2.67
- MACD
- MCRB 0.00
- ALGS -0.38
- Stochastic Oscillator
- MCRB 45.58
- ALGS 4.38
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.